Michelle Simpson, PharmD, BCSCP, MWC | Editor-in-Chief, Infusion Journal

Infusion therapy continues to evolve. Medications once largely confined to hospitals and infusion centers are increasingly administered at home. Biosimilars have expanded therapeutic options. Clinical decision support systems have grown more sophisticated. As our capabilities expand, so does our responsibility to ensure that innovation enhances care rather than complicates it.

In this issue of Infusion Journal, 3 articles examine infusion practice from distinct yet connected perspectives: clinical decision support optimization, patient perceptions shaped by social determinants of health, and real-world dosing strategies for infliximab in the home setting.

When Safety Tools Become Safety Risks
Drug utilization review (DUR) alerts are designed to protect patients by flagging potential drug-drug interactions, duplicate therapies, allergies, and dosing concerns. In the article titled “Evaluation of Overridden Drug Utilization Review (DUR) Alerts in an Ambulatory Pharmacy Dispensing System: Patterns, Documentation Practices, and Opportunities for Optimization,” the authors conducted a retrospective evaluation of overridden DUR alerts. The study found that the volume of alerts, over 93,000 in just 3 months, can create an unintended hazard called alert fatigue.

When 89% of overrides are marked simply as “Clinician Reviewed” and only 1.2% of severe drug-drug alerts include explanatory comments, we face an uncomfortable truth. High-volume alert environments risk reducing thoughtful clinical decision-making to reflexive or automated responses. The issue is not that pharmacists lack diligence. Its imprecise systems can dilute attention. Duplicate therapy alerts that ignore timing or clinical context, and drug-food alerts that may be better suited for counseling than dispensing review, contribute significantly to alert burden. For infusion practice, where biologics, immunoglobulins, and complex therapies are common, clarity in clinical decision support is important. Optimization does not mean fewer safeguards; it means smarter ones. High-severity alerts should demand meaningful documentation. Low-value alerts should be refined or restructured. Technology should amplify expertise, not compete with it.

The Home as a Clinical Environment
At the same time, infusion care is increasingly delivered beyond traditional walls. The article, “Social Determinants of Health Impact on Patient Perception within a Home Infusion and Specialty Pharmacy Setting,” surveyed home infusion patients and reported on the results that reinforce what many in the field have observed. Patients value home infusion not only clinically but also personally. They overwhelmingly reported time and cost savings, improved work-life balance, strong perceptions of safety at home, and meaningful improvements in mood. More than 80% of patients surveyed rated mood improvement at the highest level when comparing home infusion to facility-based care. These are transformative benefits.

The study also highlights disparities. Nearly 30% reported unreliable transportation if home infusion were unavailable. Approximately half lacked a designated caregiver. These realities underscore a critical point. Home infusion is not only a site of care but also a model that directly intersects with economic stability, access, environment, and social support. For infusion providers, this means our responsibilities extend beyond medication delivery. We are navigating transportation barriers, caregiver limitations, insurance coverage constraints, and varying levels of health literacy. Designing patient-centered systems requires intentional attention to these non-clinical determinants.

Dose Escalation and the Complexity of Real-World Care
Clinical complexity does not diminish at home; it often increases. The authors of the article, “Utilization and Tolerability of Alternative Infliximab and Biosimilar Dosing Strategies Among Adult Patients in the Home Infusion Setting,” conducted a retrospective study of infliximab and biosimilar dosing strategies that illustrates this concept.

Loss of response to infliximab therapy is common, prompting dose escalation to higher doses (10 mg/kg) or shorter intervals (every 4 weeks). In this real-world home infusion analysis, doubling the dose was associated with higher rates of adverse drug reactions than shortening the interval. Importantly, 76% of adverse drug reactions were managed in the home setting, a testament to the capability and vigilance of home infusion teams. These findings highlight the operational implications of dose escalation, including increased monitoring demands, nursing coordination, scheduling complexity, and a financial impact. Alternative dosing strategies may restore clinical response, but they also introduce logistical and safety considerations. As biosimilar utilization expands and dosing strategies become more personalized, infusion providers must continually balance efficacy, tolerability, and operational feasibility.

The Converging Themes: Precision, Sustainability, Accountability
What unites these 3 studies is not simply infusion therapy but system design. DUR alerts require refinement to ensure meaningful engagement. Home infusion requires integrating social determinants into care planning. Dose escalation strategies require careful monitoring and aligned resources. Each represents a different dimension of the same overarching challenge where we are building infusion systems that are precise, sustainable, and accountable.

Precision means alerts that prioritize clinically significant risks. Sustainability means workflows that protect clinicians from burnout and patients from access barriers. Accountability means documentation that clearly reflects clinical reasoning, especially in high-risk scenarios. As infusion therapy becomes increasingly decentralized and technologically supported, the margin for poorly aligned systems narrows. Alert fatigue, fragmented communication, and unmanaged escalation protocols can erode the very safety we aim to enhance.

The future of infusion practice will not be defined solely by new molecules or expanded indications. It will be defined by how thoughtfully we design the systems that deliver them. Infusion professionals are uniquely positioned at the intersection of pharmacy, nursing practice, logistics, reimbursement, and patient experience. Few specialties demand such coordinated precision. The studies in this issue remind us that innovation alone is insufficient. Optimization must follow. Every alert configuration, scheduling protocol, documentation requirement, and dosing adjustment shapes patient outcomes. Infusion therapy is increasingly complex, but complexity need not mean difficulty or inefficiency. With intentional design, interdisciplinary collaboration, and ongoing evaluation, we can build systems that elevate both safety and patient-centered care.